Affordable Access

deepdyve-link
Publisher Website

Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial

Authors
  • Wanner, Christoph1
  • Cooper, Mark E2
  • Johansen, Odd Erik3
  • Toto, Robert4
  • Rosenstock, Julio5
  • McGuire, Darren K4
  • Kahn, Steven E6
  • Pfarr, Egon7
  • Schnaidt, Sven7
  • von Eynatten, Maximilian7
  • George, Jyothis T7
  • Gollop, Nicholas D8
  • Marx, Nikolaus9
  • Alexander, John H10
  • Zinman, Bernard11, 12
  • Perkovic, Vlado13
  • 1 Department of Medicine, Division of Nephrology, Würzburg University Clinic, Germany , (Germany)
  • 2 Department of Diabetes, Central Clinical School, Monash University, Australia , (Australia)
  • 3 Boehringer Ingelheim Norway KS, Norway , (Norway)
  • 4 University of Texas Southwestern Medical Center, USA , (United States)
  • 5 Dallas Diabetes Research Center at Medical City, USA , (United States)
  • 6 Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, Puget Sound Health Care System and University of Washington, USA , (United States)
  • 7 Boehringer Ingelheim Pharma GmbH & Co. KG, Germany , (Germany)
  • 8 Boehringer Ingelheim Pharma GmbH & Co., UK , (United Kingdom)
  • 9 Department of Internal Medicine I, Germany , (Germany)
  • 10 Duke Clinical Research Institute, USA , (United States)
  • 11 Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Canada , (Canada)
  • 12 Division of Endocrinology, Canada , (Canada)
  • 13 Faculty of Medicine, The George Institute for Global Health, University of New South Wales, Australia , (Australia)
Type
Published Article
Journal
Clinical Kidney Journal
Publisher
Oxford University Press
Publication Date
Jan 17, 2021
Volume
14
Issue
1
Pages
226–236
Identifiers
DOI: 10.1093/ckj/sfaa225
PMID: 33564423
PMCID: PMC7857804
Source
PubMed Central
Keywords
Disciplines
  • AcademicSubjects/MED00340
License
Unknown
Report this publication

Statistics

Seen <100 times